| Disaggregation of Revenue [Table Text Block] |
The following table represents our revenues disaggregated by product line (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | Product line | 2026 | | 2025 | | 2026 | | 2025 | | Consumables | $ | 289,276 | | | $ | 273,133 | | | $ | 567,551 | | | $ | 539,359 | | | Infusion Systems | 188,998 | | | 167,696 | | | 368,602 | | | 333,996 | | Vital Care (1) | 73,409 | | | 108,037 | | | 145,755 | | | 280,213 | | | Total Revenues | $ | 551,683 | | | $ | 548,866 | | | $ | 1,081,908 | | | $ | 1,153,568 | |
______________________________ (1) During May 2025, we completed the sale of 60% interest in our IV Solutions business (see Note 4: Disposal of Business).
The following table represents our revenues disaggregated by geography (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | Geography | 2026 | | 2025 | | 2026 | | 2025 | | United States | $ | 349,901 | | | $ | 335,432 | | | $ | 665,404 | | | $ | 723,676 | | | Europe, the Middle East and Africa | 95,069 | | | 99,059 | | | 199,745 | | | 194,747 | | | APAC | 55,632 | | | 58,404 | | | 113,930 | | | 117,816 | | | Other Foreign | 51,081 | | | 55,971 | | | 102,829 | | | 117,329 | | | Total Revenues | $ | 551,683 | | | $ | 548,866 | | | $ | 1,081,908 | | | $ | 1,153,568 | |
|
| Contract with Customer, Asset and Liability [Table Text Block] |
The following table presents the changes in our contract balances for the six months ended June 30, 2026 and 2025 (in thousands), which are included in accrued liabilities and other long-term liabilities on the condensed consolidated balance sheets: | | | | | | | Contract Liabilities | | Beginning balance, January 1, 2026 | $ | 41,233 | | | | | Equipment revenue recognized | (56,287) | | | Equipment revenue deferred due to implementation | 76,620 | | | Software revenue recognized | (18,411) | | | Software revenue deferred due to implementation | 18,608 | | Government grant income recognized(1) | (934) | | | | | Other deferred revenue recognized | (841) | | | Other deferred revenue | 1,317 | | Ending balance, June 30, 2026 | $ | 61,305 | | | | | Beginning balance, January 1, 2025 | $ | 39,403 | | | | | Equipment revenue recognized | (33,525) | | | Equipment revenue deferred due to implementation | 30,365 | | | Software revenue recognized | (6,348) | | | Software revenue deferred due to implementation | 2,473 | | Government grant income recognized(1) | (1,024) | | | | | Other deferred revenue recognized | (1,156) | | | Other deferred revenue | 390 | | Ending balance, June 30, 2025 | $ | 30,578 | |
|
| Deferred Revenue, by Arrangement, Disclosure |
As of June 30, 2026, revenue from remaining performance obligations is as follows:
| | | | | | | | | | | | | Recognition Timing | | (in thousands) | < 12 Months | | > 12 Months | | Equipment deferred revenue | $ | 44,985 | | | $ | 360 | | | Software deferred revenue | 5,946 | | | 2,223 | | Government grant deferred income(1) | 2,064 | | | 4,342 | | Other deferred revenue(2) | 1,375 | | | 10 | | | Total | $ | 54,370 | | | $ | 6,935 | |
______________________________ (1) The government grant deferred income is amortized over the life of the related depreciable asset as a reduction to depreciation expense. (2) Other deferred revenue includes pump development programs, purchased training and extended warranty.
|